


# Addressing HER2 Alterations in Advanced NSCLC With Antibody-Drug Conjugate Therapy: Updates for the Community Oncologist

## Pre-Read Materials

1


### HER2: An Oncogenic ERBB Family Member



EGFR = epidermal growth factor receptor.  
Baselga J, Swain SM. *Nat Rev Cancer*. 2009;9(7):463-475.

2


## Progress Targeting HER2 in NSCLC



T-DM1 and afatinib are not approved by the FDA for the treatment of *HER2*-altered NSCLC.  
 Mazières J, et al. *Ann Oncol.* 2016;27(2):281-286. Li BT, et al. *J Clin Oncol.* 2018;36:2532-2537.

3

## Components of ADCs



DNA = deoxyribonucleic acid; IgG = immunoglobulin G; MC = maleimidocaproyl; MCC = maleimidomethyl cyclohexane-1-carboxylate; MoA = mechanism of action.  
 Drago JZ, et al. *Nat Rev Clin Oncol.* 2021;18(6):327-344.

4